12 Best Genomics Stocks to Invest In

Page 5 of 11

7. Twist Bioscience Corporation (NASDAQ:TWST)

Number of Hedge Fund Holders: 24  

Analysts’ Upside Potential as of December 24: 46.15%

Twist Bioscience Corporation (NASDAQ:TWST) is among the Best Genomics Stocks.

TheFly reported on December 15, 2025, that Barclays kept its Overweight rating and boosted its price objective for Twist Bioscience Corporation (NASDAQ:TWST) from $37 to $39. The move was included in the company’s more comprehensive 2026 outlook report for the life sciences and diagnostics instruments industry. According to Barclays, end markets are rebounding, the last round of estimate cutbacks has mostly passed, and the healthcare industry’s most under-owned sector is still tools. Based on the company’s research note given to investors, all of these factors provide a favorable setting for the tools group to exceed expectations in 2026.

Furthermore, Twist Bioscience Corporation (NASDAQ:TWST) released fiscal 2026 guidance. The business anticipates total revenue to be between $425 million and $435 million, which implies an increase of between 13% and 15.5% year over year. Revenue for the DNA Synthesis and Protein Solutions Group is anticipated to reach $194 million to $199 million, representing a 15% to 18% rise over fiscal 2025. It is projected that the NGS Applications Group will make between $231 million and $236 million, showing a rise of 11% to 13.5%. The fiscal year 2026 gross margin is expected to go above 52%. Apart from that, the firm announced its goal to end fiscal 2026 with adjusted EBITDA breakeven in the fourth quarter.

Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology business that has created a disruptive DNA synthesis platform to industrialize biological engineering.

Page 5 of 11